Selected research
Market Analysis & Forecast
Global Lubiprostone Market Analysis and Forecast 2026-2032
Market perspective
The global Lubiprostone market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The North America market for Lubiprostone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Europe market for Lubiprostone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
Read the full market overview
Asia-Pacific market for Lubiprostone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The China market for Lubiprostone is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.
The major global companies of Lubiprostone include Takeda Pharmaceuticals. etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.
Report Includes
This report presents an overview of global market for Lubiprostone, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.
This report researches the key producers of Lubiprostone, also provides the revenue of main regions and countries. Of the upcoming market potential for Lubiprostone, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Lubiprostone revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Lubiprostone market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Lubiprostone revenue, projected growth trends, production technology, application and end-user industry.
Lubiprostone Segment by Company
Takeda Pharmaceuticals
Lubiprostone Segment by Type
8 mcg Capsules
24 mcg Capsules
Lubiprostone Segment by Application
CIC and OIC
IBS-C
Lubiprostone Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Study Objectives
1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Lubiprostone market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Lubiprostone and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Lubiprostone.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Lubiprostone in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Lubiprostone company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Lubiprostone revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- 8 mcg Capsules
- 24 mcg Capsules
Applications
- CIC and OIC
- IBS-C
Companies covered
- Takeda Pharmaceuticals
Inside the report.
1 Market Overview
- 1.1 Product Definition
- 1.2 Lubiprostone Market by Type
- 1.2.1 Global Lubiprostone Market Size by Type, 2021 VS 2025 VS 2032
- 1.2.2 8 mcg Capsules
- 1.2.3 24 mcg Capsules
- 1.3 Lubiprostone Market by Application
- 1.3.1 Global Lubiprostone Market Size by Application, 2021 VS 2025 VS 2032
- 1.3.2 CIC and OIC
- 1.3.3 IBS-C
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
2 Lubiprostone Market Dynamics
- 2.1 Lubiprostone Industry Trends
- 2.2 Lubiprostone Industry Drivers
- 2.3 Lubiprostone Industry Opportunities and Challenges
- 2.4 Lubiprostone Industry Restraints
3 Global Growth Perspective
- 3.1 Global Lubiprostone Market Perspective (2021-2032)
- 3.2 Global Lubiprostone Growth Trends by Region
- 3.2.1 Global Lubiprostone Market Size by Region: 2021 VS 2025 VS 2032
- 3.2.2 Global Lubiprostone Market Size by Region (2021-2026)
- 3.2.3 Global Lubiprostone Market Size by Region (2027-2032)
4 Competitive Landscape by Players
- 4.1 Global Lubiprostone Revenue by Players
- 4.1.1 Global Lubiprostone Revenue by Players (2021-2026)
- 4.1.2 Global Lubiprostone Revenue Market Share by Players (2021-2026)
- 4.1.3 Global Lubiprostone Players Revenue Share Top 10 and Top 5 in 2025
- 4.2 Global Lubiprostone Key Players Ranking, 2024 VS 2025 VS 2026
- 4.3 Global Lubiprostone Key Players Headquarters & Area Served
- 4.4 Global Lubiprostone Players, Product Type & Application
- 4.5 Global Lubiprostone Players Establishment Date
- 4.6 Market Competitive Analysis
- 4.6.1 Global Lubiprostone Market CR5 and HHI
- 4.6.3 2025 Lubiprostone Tier 1, Tier 2, and Tier 3
5 Lubiprostone Market Size by Type
- 5.1 Global Lubiprostone Revenue by Type (2021 VS 2025 VS 2032)
- 5.2 Global Lubiprostone Revenue by Type (2021-2032)
- 5.3 Global Lubiprostone Revenue Market Share by Type (2021-2032)
6 Lubiprostone Market Size by Application
- 6.1 Global Lubiprostone Revenue by Application (2021 VS 2025 VS 2032)
- 6.2 Global Lubiprostone Revenue by Application (2021-2032)
- 6.3 Global Lubiprostone Revenue Market Share by Application (2021-2032)
7 Company Profiles
- 7.1 Takeda Pharmaceuticals
- 7.1.1 Takeda Pharmaceuticals Company Information
- 7.1.2 Takeda Pharmaceuticals Business Overview
- 7.1.3 Takeda Pharmaceuticals Lubiprostone Revenue and Gross Margin (2021-2026)
- 7.1.4 Takeda Pharmaceuticals Lubiprostone Product Portfolio
- 7.1.5 Takeda Pharmaceuticals Recent Developments
8 North America
- 8.1 North America Lubiprostone Revenue (2021-2032)
- 8.2 North America Lubiprostone Revenue by Type (2021-2032)
- 8.2.1 North America Lubiprostone Revenue by Type (2021-2026)
- 8.2.2 North America Lubiprostone Revenue by Type (2027-2032)
- 8.3 North America Lubiprostone Revenue Share by Type (2021-2032)
- 8.4 North America Lubiprostone Revenue by Application (2021-2032)
- 8.4.1 North America Lubiprostone Revenue by Application (2021-2026)
- 8.4.2 North America Lubiprostone Revenue by Application (2027-2032)
- 8.5 North America Lubiprostone Revenue Share by Application (2021-2032)
- 8.6 North America Lubiprostone Revenue by Country
- 8.6.1 North America Lubiprostone Revenue by Country (2021 VS 2025 VS 2032)
- 8.6.2 North America Lubiprostone Revenue by Country (2021-2026)
- 8.6.3 North America Lubiprostone Revenue by Country (2027-2032)
- 8.6.4 United States
- 8.6.5 Canada
- 8.6.6 Mexico
9 Europe
- 9.1 Europe Lubiprostone Revenue (2021-2032)
- 9.2 Europe Lubiprostone Revenue by Type (2021-2032)
- 9.2.1 Europe Lubiprostone Revenue by Type (2021-2026)
- 9.2.2 Europe Lubiprostone Revenue by Type (2027-2032)
- 9.3 Europe Lubiprostone Revenue Share by Type (2021-2032)
- 9.4 Europe Lubiprostone Revenue by Application (2021-2032)
- 9.4.1 Europe Lubiprostone Revenue by Application (2021-2026)
- 9.4.2 Europe Lubiprostone Revenue by Application (2027-2032)
- 9.5 Europe Lubiprostone Revenue Share by Application (2021-2032)
- 9.6 Europe Lubiprostone Revenue by Country
- 9.6.1 Europe Lubiprostone Revenue by Country (2021 VS 2025 VS 2032)
- 9.6.2 Europe Lubiprostone Revenue by Country (2021-2026)
- 9.6.3 Europe Lubiprostone Revenue by Country (2027-2032)
- 9.6.4 Germany
- 9.6.5 France
- 9.6.6 U.K.
- 9.6.7 Italy
- 9.6.8 Russia
- 9.6.9 Spain
- 9.6.10 Netherlands
- 9.6.11 Switzerland
- 9.6.12 Sweden
- 9.6.13 Poland
10 China
- 10.1 China Lubiprostone Revenue (2021-2032)
- 10.2 China Lubiprostone Revenue by Type (2021-2032)
- 10.2.1 China Lubiprostone Revenue by Type (2021-2026)
- 10.2.2 China Lubiprostone Revenue by Type (2027-2032)
- 10.3 China Lubiprostone Revenue Share by Type (2021-2032)
- 10.4 China Lubiprostone Revenue by Application (2021-2032)
- 10.4.1 China Lubiprostone Revenue by Application (2021-2026)
- 10.4.2 China Lubiprostone Revenue by Application (2027-2032)
- 10.5 China Lubiprostone Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
- 11.1 Asia Lubiprostone Revenue (2021-2032)
- 11.2 Asia Lubiprostone Revenue by Type (2021-2032)
- 11.2.1 Asia Lubiprostone Revenue by Type (2021-2026)
- 11.2.2 Asia Lubiprostone Revenue by Type (2027-2032)
- 11.3 Asia Lubiprostone Revenue Share by Type (2021-2032)
- 11.4 Asia Lubiprostone Revenue by Application (2021-2032)
- 11.4.1 Asia Lubiprostone Revenue by Application (2021-2026)
- 11.4.2 Asia Lubiprostone Revenue by Application (2027-2032)
- 11.5 Asia Lubiprostone Revenue Share by Application (2021-2032)
- 11.6 Asia Lubiprostone Revenue by Country
- 11.6.1 Asia Lubiprostone Revenue by Country (2021 VS 2025 VS 2032)
- 11.6.2 Asia Lubiprostone Revenue by Country (2021-2026)
- 11.6.3 Asia Lubiprostone Revenue by Country (2027-2032)
- 11.6.4 Japan
- 11.6.5 South Korea
- 11.6.6 India
- 11.6.7 Australia
- 11.6.8 Taiwan
- 11.6.9 Southeast Asia
12 South America, Middle East and Africa
- 12.1 SAMEA Lubiprostone Revenue (2021-2032)
- 12.2 SAMEA Lubiprostone Revenue by Type (2021-2032)
- 12.2.1 SAMEA Lubiprostone Revenue by Type (2021-2026)
- 12.2.2 SAMEA Lubiprostone Revenue by Type (2027-2032)
- 12.3 SAMEA Lubiprostone Revenue Share by Type (2021-2032)
- 12.4 SAMEA Lubiprostone Revenue by Application (2021-2032)
- 12.4.1 SAMEA Lubiprostone Revenue by Application (2021-2026)
- 12.4.2 SAMEA Lubiprostone Revenue by Application (2027-2032)
- 12.5 SAMEA Lubiprostone Revenue Share by Application (2021-2032)
- 12.6 SAMEA Lubiprostone Revenue by Country
- 12.6.1 SAMEA Lubiprostone Revenue by Country (2021 VS 2025 VS 2032)
- 12.6.2 SAMEA Lubiprostone Revenue by Country (2021-2026)
- 12.6.3 SAMEA Lubiprostone Revenue by Country (2027-2032)
- 12.6.4 Brazil
- 12.6.5 Argentina
- 12.6.6 Chile
- 12.6.7 Colombia
- 12.6.8 Peru
- 12.6.9 Saudi Arabia
- 12.6.10 Israel
- 12.6.11 UAE
- 12.6.12 Turkey
- 12.6.13 Iran
- 12.6.14 Egypt
13 Concluding Insights
14 Appendix
- 14.1 Reasons for Doing This Study
- 14.2 Research Methodology
- 14.3 Research Process
- 14.4 Authors List of This Report
- 14.5 Data Source
- 14.5.1 Secondary Sources
- 14.5.2 Primary Sources
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst